Conquering Rare Cancer at the Speed of Insight
Be the scientist who finds the breakthrough with Zeta. Discover combination therapies, design trials, create drugs, and validate hypotheses... in minutes, not months.
The rare cancer paradox
Individually rare, collectively burdensome, economically neglected. Critical insights scattered across fragmented data sources with no centralized infrastructure to connect them.
The fragmentation challenge
Zeta unifies the landscape
An agentic intelligence layer integrating curated rare cancer databases, clinical trial registries, research literature, and bioinformatics tools. Recursive reasoning loops traverse unified biomedical ontologies, transforming fragmented knowledge into connected therapeutic insights.
Built for researchers advancing therapies where traditional pharmaceutical economics fail patients.
The world's deepest rare cancer knowledge
Four specialized databases, unified into a single ontology connecting genes, drugs, trials, and phenotypes
Rare Cancers Knowledge Base
Curated database linking rare cancer types to therapeutic compounds, biomarkers, and clinical research
Cancer Drug Database
Comprehensive cancer drug database with FDA approval status, clinical trial data, and molecular targets
Clinical Trials Database
Self-hosted index of all registered clinical studies from ClinicalTrials.gov via AACT
Rare Cancers Library
Comprehensive document library with research papers, clinical guidelines, and treatment protocols
Connected to real-time scientific knowledge
Live access to authoritative medical databases and regulatory sources
PubMed / PMC
Real-time literature search across PubMed and PubMed Central
ORPHANET
European rare disease database with expert-curated information
NCI Thesaurus
Standardized cancer terminology ontology from the National Cancer Institute
OpenFDA Drug Labels
Live access to drug labels, adverse events, and drug interactions
Human Phenotype Ontology
Disease-symptom relationships and phenotypic abnormalities
Ontology Lookup Service
Cross-database entity linking and standardized vocabularies
Molecular Features
Calculate physicochemical properties including molecular weight, logP, TPSA, and drug-likeness
SMILES Validation
Validate chemical structures and generate molecular diagrams from SMILES strings
ChEMBL & PubChem
Query molecular information, bioactivity data, and compound properties
All data enriched and validated against authoritative medical sources
Advanced AI and specialized models
Recursive agents and machine learning models transform data into breakthrough insights
AI-Powered Chemical Reasoning
Advanced AI reasoning model that thinks through complex chemistry problems step-by-step. ETHER0 explores drug design opportunities by generating hypotheses, evaluating molecular structures, and proposing novel therapeutic candidates. It identifies promising scaffolds and optimizes drug-like properties for rare cancer targets.
Read about ETHER0
Blood-Brain Barrier Prediction
Industry-leading 16-model ML ensemble predicting blood-brain barrier permeability. Trained on 7,000+ compounds for targeted therapy development in CNS rare cancers. Identifies which treatments can effectively reach brain tumors and neurological targets.
Visit PredictBBB.aiRecursive Agentic Intelligence
Your co-scientist for discovering novel therapies and unlocking clinical trials for rare cancers. Zeta investigates autonomously across multiple rounds of inquiry, deciding when to dive deeper and when to synthesize findings.
Traditional Research
Manual Literature Mining
Search PubMed for rare cancer papers, sift through abstracts one by one, no connections between entities
3-4 hoursClinical Trial Hunting
Navigate ClinicalTrials.gov filters, decode eligibility criteria, manually match patient biomarkers
2-3 hoursDrug-Target Mapping
Cross-reference FDA labels, ORPHANET disease data, and molecular databases separately
2-3 hoursEvidence Synthesis
Compile fragmented findings from disparate sources, manually identify therapeutic opportunities
2-4 hoursManual, fragmented, time-intensive
Research with Zeta
Natural Language Query
Ask your research question in plain English about rare cancer therapies, biomarkers, or trials
InstantAutonomous Multi-Source Search
Zeta simultaneously queries rare cancer databases, clinical trials, literature, and drug data
SecondsRecursive Investigation
AI analyzes initial findings, decides which leads warrant deeper investigation, executes follow-up searches
MinutesSynthesized Insights
Citation-backed analysis with drug candidates, trial matches, biomarker correlations, and knowledge graphs
CompleteAutonomous, integrated, accelerated
See Zeta in action
From question to insight in minutes. Watch how Zeta transforms rare cancer research with autonomous intelligence.